These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28194852)

  • 21. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
    Woodcock F; Doble B;
    Med Decis Making; 2018 Nov; 38(8):954-967. PubMed ID: 30226101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.
    Versteegh MM; Leunis A; Luime JJ; Boggild M; Uyl-de Groot CA; Stolk EA
    Med Decis Making; 2012; 32(4):554-68. PubMed ID: 22114301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of EQ-5D-3L health utility scores using five country-specific tariffs in a rural population aged 45-69 years in Hua county, Henan province, China.
    Wang H; Cao C; Guo C; He Y; Li F; Xu R; Liu M; Liu Z; Pan Y; Liu F; Liu Y; Li J; Cai H; He Z; Ke Y
    Health Qual Life Outcomes; 2020 Jul; 18(1):228. PubMed ID: 32660494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease.
    Goldsmith KA; Dyer MT; Buxton MJ; Sharples LD
    Health Qual Life Outcomes; 2010 Jun; 8():54. PubMed ID: 20525323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.
    Thompson NR; Lapin BR; Katzan IL
    Pharmacoeconomics; 2017 Nov; 35(11):1167-1176. PubMed ID: 28710740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation study of the prototype of a disease-specific index measure for health-related quality of life in dementia.
    Schölzel-Dorenbos CJ; Arons AM; Wammes JJ; Rikkert MG; Krabbe PF
    Health Qual Life Outcomes; 2012 Sep; 10():118. PubMed ID: 23009579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping the Beck Depression Inventory to the EQ-5D-3L in Patients with Depressive Disorders.
    Grochtdreis T; Brettschneider C; Hajek A; Schierz K; Hoyer J; Koenig HH
    J Ment Health Policy Econ; 2016 Jun; 19(2):79-89. PubMed ID: 27453455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
    Kay S; Ferreira A
    Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.
    Kim SH; Jo MW; Kim HJ; Ahn JH
    Health Qual Life Outcomes; 2012 Dec; 10():151. PubMed ID: 23244763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Item-Response Mapping from General Health Questionnaire Responses to EQ-5D-3L Using a General Population Sample from England.
    Webb EJD
    Appl Health Econ Health Policy; 2023 Mar; 21(2):327-346. PubMed ID: 36372819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of algorithms to estimate EQ-5D and derive health utilities from WHOQOL-HIV Bref: a mapping study.
    Castro R; De Boni RB; Perazzo H; Grinsztejn B; Veloso VG; Ribeiro-Alves M
    Qual Life Res; 2020 Sep; 29(9):2497-2508. PubMed ID: 32451983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EQ-5D-3L health state utility values in transfusion-dependent thalassemia patients in Malaysia: a cross-sectional assessment.
    Shafie AA; Chhabra IK; Wong JHY; Mohammed NS
    Health Qual Life Outcomes; 2021 Jan; 19(1):10. PubMed ID: 33413416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference.
    Nolan CM; Longworth L; Lord J; Canavan JL; Jones SE; Kon SS; Man WD
    Thorax; 2016 Jun; 71(6):493-500. PubMed ID: 27030578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People's Quality of Life Brief Questionnaire (OPQoL-Brief) Scores.
    Kaambwa B; Ratcliffe J
    Patient; 2018 Feb; 11(1):39-54. PubMed ID: 28623629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index.
    Su J; Liu T; Li S; Zhao Y; Kuang Y
    J Med Econ; 2020 Jul; 23(7):737-743. PubMed ID: 32223358
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
    Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
    Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychometric properties of the EuroQol Five Dimensional Questionnaire (EQ-5D-3L) in caregivers of autistic children.
    Khanna R; Jariwala K; Bentley JP
    Qual Life Res; 2013 Dec; 22(10):2909-20. PubMed ID: 23615959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.
    Rencz F; Lakatos PL; Gulácsi L; Brodszky V; Kürti Z; Lovas S; Banai J; Herszényi L; Cserni T; Molnár T; Péntek M; Palatka K
    Qual Life Res; 2019 Jan; 28(1):141-152. PubMed ID: 30225788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
    Lamu AN; Olsen JA
    Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.